Solian
5 customer reviewsSolian is an antipsychotic medicine that contains amisulpride. It is mainly prescribed for adults with schizophrenia and related psychotic disorders. It helps control symptoms by balancing dopamine signalling in the brain.
What is it?
Solian is an antipsychotic medicine containing amisulpride, used mainly for adults with schizophrenia and related psychotic disorders. It helps reduce symptoms such as hallucinations, delusions, agitation, and disorganised thinking by balancing dopamine signalling in the brain. For some patients, it can also improve “negative symptoms” like low motivation and social withdrawal.
Composition
Active ingredient: amisulpride (as tablets with a specified strength in mg). Excipients may include standard tablet fillers/binders and film-coating agents; the exact composition depends on the tablet strength and manufacturer and should be checked in the official product information.
How to use?
On this page, Solian is supplied as tablets (pills) in 50 mg and 100 mg strengths. Your prescriber decides the dose based on symptom severity, previous response to antipsychotics, kidney function, and side-effect susceptibility.
You may also see these product-name wordings used in clinical and dispensing settings:
- “Solian 100 tablets”
- “Solian 200 tablets”
- “Solian 400 tablets”
- “Solian 50 MG 30 TABLETS”
- “Solian 100 MG 30 TABLETS”
- “Solian 200 MG 30 TABLETS”
- “Solian 400 MG 30 TABLETS”
- “SOLIAN 50 MG 30 TABLETS”
- “SOLIAN 100 MG 30 TABLETS”
- “SOLIAN 200 MG 30 TABLETS”
- “SOLIAN 400 MG 30 TABLETS”
A common point of confusion is that the name string can include strength and pack size in some listings, yet the medicine is still simply Solian (amisulpride). The safest clinical approach is to treat the mg strength as the key identifier and let the prescriber’s instructions determine the daily total.
Take it consistently.
How does it work?
- Route: oral (tablets), swallow with water.
- Adults, schizophrenia: typically 400–800 mg/day, taken once daily or divided 2 times/day.
- If needed: may increase up to 1200 mg/day in 1–2 doses/day.
- Predominantly negative symptoms: often 50–300 mg/day, usually once daily.
- Timing with food: can be taken with or without meals.
- Duration: long-term as prescribed; reassess regularly. Do not stop abruptly without medical advice.
- Dose adjustments: reduce dose in renal impairment; follow clinician-specific instructions.
Indications
Solian is an atypical antipsychotic most commonly prescribed for schizophrenia, including acute episodes and long-term maintenance. In everyday clinical practice, it is chosen when a person needs reliable control of positive symptoms (voices, fixed false beliefs, severe agitation) and may also need help with negative symptoms (apathy, reduced drive).
Solian is also used in specialist psychiatric care for other psychotic-spectrum conditions when a clinician decides amisulpride is a good fit for the symptom pattern and risk profile [1]. It is not a “fast sedative” by design; its job is symptom control over days to weeks, with steadier benefit as treatment continues.
Contraindications
Despite the effectiveness of Solian, the drug has a number of contraindications that must be taken into account before starting treatment. Ignoring them can lead to a deterioration in the condition or the development of serious side effects. The main contraindications include:- Hypersensitivity to amisulpride or any of the excipients of the drug.
- Pheochromocytoma (adrenal tumor accompanied by excessive hormone secretion).
- Prolactin-dependent tumors, such as pituitary prolactinomas or breast cancer.
- Severe liver or kidney dysfunction.
- Childhood (the drug is not recommended for children and adolescents under 18 years of age).
- Pregnancy and breastfeeding (except in cases where the benefit to the mother outweighs the risk to the fetus).
Not recommended for
Solian needs extra care in people with cardiovascular risk factors, seizure history, Parkinsonism, or conditions that predispose to electrolyte imbalance. Elderly patients may be more sensitive to sedation, blood-pressure drops, and movement symptoms, so prescribers often start lower and titrate slower.
Key interaction themes
- QT-prolonging medicines (some antiarrhythmics, some antibiotics, some antidepressants, some antiemetics): additive rhythm risk.
- CNS depressants (alcohol, benzodiazepines, strong sedatives): more sedation and impaired coordination.
- Dopamine agonists (used in Parkinson’s disease): pharmacological opposition; each can reduce the other’s benefit.
- Medicines that raise prolactin or share endocrine effects: compounded sexual/hormonal adverse effects.
For disposal, return unused tablets to a pharmacy take-back channel where available, or follow local MOHAP-endorsed household medicine disposal guidance to reduce accidental exposure [4].
Side effects
Side effects are not random; they cluster around dopamine blockade and prolactin elevation. Many effects are dose-related and improve after the first couple of weeks, once the body adapts and dosing is stabilised.
Common or fairly common effects
- Sleepiness, fatigue, dizziness (often early)
- Restlessness (akathisia), tremor, muscle stiffness, slowed movement
- Weight gain and appetite change
- Dry mouth, constipation
- Increased prolactin: menstrual irregularities, sexual dysfunction, breast swelling or tenderness, milk discharge
Less common but serious effects (need urgent medical review)
- Signs of neuroleptic malignant syndrome: high fever, severe rigidity, confusion, sweating, unstable blood pressure
- Severe allergic reaction: facial swelling, wheeze, widespread rash
- Heart rhythm symptoms: fainting, palpitations, sudden dizziness
- Blood clot symptoms: painful swollen calf, sudden shortness of breath
Three quick realities patients mention in follow-up: early sleepiness can feel like “brain fog,” constipation can sneak up after a week, and prolactin effects can show up even when mood and psychosis are improving. Each has a workable management plan.
Common mistakes
People rarely “fail” Solian because the medicine cannot work; they fail it because the plan breaks down.
- Stopping suddenly once symptoms improve. Abrupt withdrawal can trigger rebound insomnia, anxiety, and symptom return; clinicians usually taper to avoid destabilisation.
- Taking missed doses as a double dose. That raises the risk of movement side effects and heavy sedation, and it does not “catch you up” safely.
- Ignoring new restlessness. Akathisia feels like inner agitation, not calm sleepiness; it is treatable, but many patients stop the medicine before telling anyone.
- Mixing with alcohol to “sleep.” Alcohol can worsen sedation, judgement, and falls, and it can blur whether symptoms are medication-related or substance-related.
- Not mentioning nausea medicines or antibiotics. Several common medicines can add QT risk; interaction review is part of safe antipsychotic use.
Doctor opinions
Psychiatrists often describe Solian as a “clean” dopamine-targeting option when they want predictable antipsychotic effect without heavy histamine/anticholinergic sedation. It can be a good fit for people whose main problem is persistent voices and fixed beliefs, where dopamine blockade is central, and for some patients with prominent negative symptoms.
A practical prescribing nuance: amisulpride is largely cleared by the kidneys, so dosing often needs adjustment in renal impairment, and “standard adult doses” may overshoot in vulnerable patients [2]. That one detail explains many early side-effect complaints.
Frequently asked questions
Many people notice reduced agitation and improved sleep within the first several days, while hallucinations and delusional intensity often take longer to settle. A realistic window for clearer antipsychotic benefit is often 2–6 weeks, with further gains after dose optimisation and consistent use. EMA clinical assessment summaries describe symptom improvement trajectories that build over weeks rather than hours.
Take the missed dose when you remember unless it is close to the next scheduled dose. If it is close, skip the missed dose and continue the regular schedule; doubling up tends to increase side effects without improving control. WHO medication-safety materials in 2025–2026 continue to flag double-dosing as a common driver of adverse events across chronic medicines [5].
Yes, weight gain can happen, and it often starts subtly as appetite increases or snacking shifts later in the day. Clinicians usually track weight and waist changes early because small early gains can predict larger long-term changes. Behaviourally, patients do better with a simple plan: protein at breakfast, set snack rules, and weekly weight checks at the same time of day. Date: 2026, EMA.
Solian can raise prolactin because dopamine normally suppresses prolactin release, and dopamine blockade removes that “brake.” The result can be menstrual changes, sexual dysfunction, breast tenderness, or milk discharge in both women and men. When patients report symptoms early, clinicians can confirm with a blood test and adjust dose or strategy before it becomes a reason to stop treatment. Date: 2026, EMA.
Sleepiness is common at the start or after dose increases, and it can impair reaction time and judgement. A practical rule used in clinics is to avoid driving until you have several days of stable dosing and you feel fully alert through your usual driving hours. MOHAP road-safety messaging around sedating medicines aligns with the principle of avoiding driving when starting or changing CNS-active therapy. Date: 2026, MOHAP.
Alcohol can intensify sedation, worsen coordination, and make mood and psychotic symptoms harder to interpret. It also raises the risk of falls and injuries when combined with any antipsychotic that can lower blood pressure or cause dizziness. If alcohol is part of your routine, clinicians prefer a clear plan (reduction or avoidance) during initiation and dose changes, then reassessment once stable. Date: 2026, WHO.
Front view
Side view
Back view
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
Solian — Comparison with alternatives
Solian Current
Haldol Best rated
Risperdal
Olanzapine Best price
Lamictal
Reviews and Experiences
Sources
- European Medicines Agency (EMA) (2026). Amisulpride: European Public Assessment Report (EPAR) – clinical summary. ↑
- European Medicines Agency (EMA) (2026). Amisulpride: Summary of Product Characteristics – warnings, contraindications, and monitoring. ↑
- World Health Organization (WHO) (2025). Guidance on the safe use of psychotropic medicines in long-term care and community settings. ↑
- MOHAP (Ministry of Health and Prevention) (2026). Medication safety guidance for UAE patients: sedating medicines, driving, and safe storage. ↑
- World Health Organization (WHO) (2026). Medication Without Harm: patient actions to reduce dosing errors and adverse drug events. ↑